TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15809123
Drug: Racemic bupivacaine
Normalized name: Racemic bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Racemic bupivacaine (2.5 mg) + fentanyl (25 microg)
Study: 15809123
Drug: L-bupivacaine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-bupivacaine (2.5 mg) + fentanyl (25 microg)
Study: 15809123
Drug: Racemic bupivacaine
Normalized name: Racemic bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Racemic bupivacaine and L-bupivacaine
Study: 12114402
Drug: CTP37-DT vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTP37-DT vaccine administered intramuscularly on days 0, 28, and 70.
Study: 7553242
Drug: Oxymetazoline nasal
Normalized name: oxymetazoline nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline nasal spray alone
Study: 274263
Drug: 0.2% SnF2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% SnF2 solution
Study: 274263
Drug: 0.3% SnF2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% SnF2 solution
Study: 30989175
Drug: Prolonged intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged intravenous therapy
Study: 25536008
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (140 mL, providing 12.9 mmol of nitrate)
Study: 16448575
Drug: Primaquine (PQ)
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primaquine (PQ) 45 mg
Study: 16448575
Drug: Bulaquine (BQ)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bulaquine (BQ) 75 mg
Study: 15561834
Drug: Amoxicillin-clavulanate exposure
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate exposure during the previous 3 months
Study: 3904205
Drug: Radiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation treatment alone
Study: 9778203
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate (5 mg/d)
Study: 9778203
Drug: Nifedipine coat
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine coat core (30 mg/d)
Study: 9778203
Drug: Nifedipine gastrointestinal
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine gastrointestinal therapeutic system (GITS) (30 mg/d)
Study: 31077519
Drug: Individualized Occupational
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized Occupational Therapy (IOT)
Study: 31077519
Drug: Group Occupational
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Occupational Therapy (GOT) alone
Study: 31077519
Drug: Type of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type of occupational therapy
Study: 27535371
Drug: Control (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (inert lotion)
Study: 24777691
Drug: Colesevelam 1.5-4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam 1.5-4.5 g/day
Study: 22798322
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids with vitamin D deficiency
Study: 22798322
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids with vitamin D insufficiency
Study: 22798322
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids with vitamin D sufficiency
Study: 21055090
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (control group)
Study: 19969409
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate (E2V) and dienogest (DNG) administered over 20 cycles with a specific dosing schedule: E2V 3 mg on days 1 and 2, E2V 2 mg/DNG 2 mg on days 3-7, E2V 2 mg/DNG 3 mg on days 8-24, E2V 1 mg on days 25 and 26, and placebo on days 27 and 28.
Study: 15457373
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg/d)
Study: 11145109
Drug: High-fat (40%
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat (40% of daily energy), high-monounsaturated-fat diet
Study: 11145109
Drug: Low-fat (30%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat (30% of daily energy) diet
Study: 3596872
Drug: O-(beta-hydroxyethyl)-rutosides (HR)
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O-(beta-hydroxyethyl)-rutosides (HR) 3 g/day for 28 days
Study: 29871226
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral health education (Control)
Study: 26039521
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg) + Ezetimibe (10 mg)
Study: 26039521
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg) + Placebo
Study: 23222038
Drug: Cognitive analytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive analytic therapy (CAT) - 24 sessions over 10 months
Study: 21983067
Drug: Maternal probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal probiotic treatment
Study: 11020001
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with interferon alpha-2b and ribavirin for 24 weeks
Study: 11020001
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b monotherapy for 48 weeks
Study: 9279534
Drug: L-arginine (0.52
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (0.52 mg kg‐1 min‐1)
Study: 8334811
Drug: Clenbuterol treatment
Normalized name: clenbuterol
DrugBank: Clenbuterol (DB01407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenbuterol treatment for 4 weeks postoperatively
Study: 8334811
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 4 weeks postoperatively
Study: 3595666
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methylprednisolone added to metoclopramide
Study: 27543277
Drug: Pakistani almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pakistani almonds (10 g/day)
Study: 27543277
Drug: American almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: American almonds (10 g/day)
Study: 26685032
Drug: Impulsivity-focused group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impulsivity-focused group intervention (8 weekly sessions)
Study: 23414589
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with three cycles of TPF followed by concurrent chemoradiotherapy
Study: 23414589
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy alone with two cycles of bolus cisplatin
Study: 23414589
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by chemoradiotherapy
Study: 16750345
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of DHA daily for 14 days
Study: 16750345
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of olive oil as placebo daily for 14 days
Study: 10871462
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy changes
Study: 3885921
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation at 6 L/min via nonrebreathing face masks for 15 minutes or less
Study: 3885921
Drug: Air inhalation
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air inhalation at 6 L/min via nonrebreathing face masks for 15 minutes or less
Study: 30118351
Drug: No periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No periodontal therapy (control)
Study: 15177521
Drug: Amlodipine besylate/benazepril
Normalized name: amlodipine besylate/benazepril 5 mg-10 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine besylate/benazepril HCl combination therapy (5/20 mg/d titrated to 10/20 mg/d)
Study: 15177521
Drug: Amlodipine besylate/benazepril
Normalized name: amlodipine besylate/benazepril 5 mg-10 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine besylate/benazepril HCl combination therapy
Study: 15177521
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate monotherapy (5 mg/d titrated to 10 mg/d)
Study: 15177521
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate monotherapy
Study: 9498468
Drug: ETEC/rCTB vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETEC/rCTB vaccine (E003)
Study: 3264141
Drug: Cardioplegic solution
Normalized name: cardioplegic solution no.2
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardioplegic solution without allopurinol (Group 1)
Study: 3264141
Drug: Cardioplegic solution
Normalized name: cardioplegic solution no.2
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardioplegic solution with 100 mg allopurinol (Group 2)
Study: 30789807
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of calcium and 800 IU vitamin D supplementation
Study: 24518763
Drug: Surgeon administered
Normalized name: sturgeon, unspecified preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgeon administered regional field infiltration with bupivacaine
Study: 22338626
Drug: Probiotic yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yogurt (200 g/day)
Study: 22338626
Drug: Conventional yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional yogurt (200 g/day)
Study: 17627016
Drug: Specific IgE
Normalized name: BSA specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgE to common aeroallergens (defined as >or=0.35 kU/L)
Study: 17627016
Drug: Total serum
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total serum IgE levels before treatment
Study: 15899724
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg/day
Study: 15899724
Drug: glimepiride 2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: glimepiride 2 mg/day
Study: 9650373
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (0.5 mg administered intracervically)
Study: 9650373
Drug: Estradiol gel
Normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol gel (150 mg administered intravaginally)
Study: 1850128
Drug: High fat-low
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat-low fiber diet (96 g fat/day, 6 g fiber/day)
Study: 1850128
Drug: Low fat-high
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat-high fiber diet (33 g fat/day, 41 g fiber/day)
Study: 27370941
Drug: Paracetamol 1g
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 1g IV
Study: 25342708
Drug: AG2 (bed
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG2 (bed rest and six periods of 5 min AG daily)
Study: 25342708
Drug: AG1 (bed
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG1 (bed rest and 30 min of AG daily)
Study: 25524951
Drug: Blood 25-hydroxyvitamin
Normalized name: SUS SCROFA BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood 25-hydroxyvitamin D concentration <50 nmol/L
Study: 23474735
Drug: Conventional out-patient
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional out-patient physical therapy
Study: 11783697
Drug: ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftazidime 2 g t.i.d. (n=12)
Study: 11783697
Drug: imipenem/cilastatin 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: imipenem/cilastatin 1 g t.i.d. (n=15)
Study: 594790
Drug: Diethylstilbestrol (DES,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylstilbestrol (DES, 5 mg/day)
Study: 28422269
Drug: Wake therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wake therapy
Study: 27804203
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy (30 min daily for 9 weeks)
Study: 27804203
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment experience
Study: 21359522
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg) plus rebamipide (300 mg)
Study: 11876701
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg)
Study: 19843657
Drug: Lu 35‐138
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu 35‐138 (I(Kr)‐blocking antipsychotic compound)
Study: 15214594
Drug: Postoperative 5-FU-based
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postoperative 5-FU-based chemotherapy combined with irradiation
Study: 15214594
Drug: Preoperative combined-modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative combined-modality therapy
Study: 15214594
Drug: Oral capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capecitabine (Xeloda) as a radiation enhancer
Study: 9105077
Drug: Inspiratory elastic
Normalized name: elastin
DrugBank: Elastin (human) (DB15364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory elastic load of 18 cm H2O/L
Study: 2630295
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 mg) in decaffeinated coffee
Study: 235013
Drug: Pimozide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide (mean 18.8 mg/day for 6 weeks)
Study: 25228137
Drug: Ivermectin 1%
Normalized name: IVERMECTIN 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 1% cream (IVM 1%) once daily
Study: 25228137
Drug: Metronidazole 0.75%
Normalized name: METRONIDAZOLE 0.75% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 0.75% cream (MTZ 0.75%) twice daily
Study: 21531671
Drug: Actual Reiki
Normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Actual Reiki therapy
Study: 19750999
Drug: Prophylactic radiation
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic radiation therapy (700 cGy)
Study: 15607618
Drug: cerivastatin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: cerivastatin (0.3 mg/day)
Study: 15607618
Drug: candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: candesartan (8 mg/day)
Study: 15607618
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (24 normocholesterolemic subjects without any therapy)
Study: 8445152
Drug: 50 mU
Normalized name: Tu Mu Xiang
DrugBank: Inula helenium root (DB14350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mU biosynthetic human growth hormone (r‐hGH) bolus
Study: 8445152
Drug: 80 mU/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mU/h iv infusion of r‐hGH
Study: 24419019
Drug: Electromyography-triggered neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromyography-triggered neuromuscular stimulation and mirror therapy (ETMS-MT)
Study: 18562328
Drug: Anthracycline-docetaxel-based sequential
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline-docetaxel-based sequential or concurrent chemotherapy
Study: 12437859
Drug: Enhanced care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced care patients received bimonthly protective treatment and twice-daily chlorhexidine mouthrinses to treat gingivitis
Study: 12437859
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group subjects received professional dental protective treatment and checkups at baseline, 6 months, and 1 year, plus dental care
Study: 10851564
Drug: Low-dose fosinopril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fosinopril (10 mg/d)
Study: 28461283
Drug: Minimal-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal-treatment control
Study: 17360294
Drug: 10-g Semmes-Weinstein
Normalized name: lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-g Semmes-Weinstein monofilament test
Study: 15347374
Drug: Injective immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injective immunotherapy with a maintenance dose of 7.2 microg of Amb a 1 administered at 4-week intervals
Study: 21439539
Drug: hs-CRP >2
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP >2 mg/L and BMS
Study: 21439539
Drug: hs-CRP >2
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP >2 mg/L and DES
Study: 21439539
Drug: hs-CRP ≤2
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP ≤2 mg/L and BMS
Study: 21439539
Drug: hs-CRP ≤2
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP ≤2 mg/L and DES
Study: 21439539
Drug: BMS +
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS + CRP ≤2 mg/L
Study: 31341122
Drug: Implant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant treatment
Study: 8497701
Drug: Methotrexate 30
Normalized name: METHOTREXATE 30MG/0.6ML AUTO INJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 30 mg week-1
Study: 29138275
Drug: 1-h blood
Normalized name: SUS SCROFA BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-h blood glucose measurement (≥8.6 mmol/L)
Study: 29138275
Drug: 2-h blood
Normalized name: SUS SCROFA BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-h blood glucose measurement (≥7.8 mmol/L)
Study: 20886788
Drug: Electroacupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture combined with western medicine (Simvastatin, Glipizide XL, Felodipine sustained-release tablets)
Study: 20886788
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine only (Simvastatin, Glipizide XL, Felodipine sustained-release tablets)
Study: 22441222
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between groups after treatment
Study: 10981087
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin therapy in patients with hypertension
Study: 8877020
Drug: Metamizol 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol 25 mg kg‐1
Study: 8877020
Drug: Pethidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 0.4 mg kg‐1
Study: 1890910
Drug: Nicardipine (60‐120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (60‐120 mg daily)
Study: 1890910
Drug: Propranolol (120‐240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120‐240 mg daily)
Study: 6366719
Drug: Cimetidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (600 mg/m2 body surface/day for 4 months)
Study: 20038244
Drug: Fluconazole (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (1200 mg per day) alone
Study: 20038244
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluconazole (1200 mg per day) and flucytosine (100 mg/kg per day) followed by fluconazole (800 mg per day)
Study: 12004166
Drug: Continuous low-level
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous low-level heat wrap therapy (40 C, 8 hours/day)
Study: 369652
Drug: Other two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other two agents (Bendrofluazide and Spironolactone)
Study: 31208509
Drug: High-dose caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose caffeine (10 mg/kg maintenance dose after 20 mg/kg loading dose)
Study: 31208509
Drug: Low-dose caffeine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose caffeine (5 mg/kg maintenance dose after 20 mg/kg loading dose)
Study: 31208509
Drug: High-dose caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose caffeine
Study: 26731724
Drug: Temsirolimus (25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (25mg weekly IV infusions)
Study: 17122357
Drug: Intranasal leptin
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal leptin delivery; superpotent leptin-receptor agonists; manipulation of SOCS-3, PTP-1B, ciliary neurotrophic factor; traditional interventions for weight loss.
Study: 17122357
Drug: Activation of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activation of melanocortin receptors; activation of 5-HT2C and 5-HT1B receptors.
Study: 17122357
Drug: Inhibition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibition of neuropeptide Y, melanin-concentrating hormone, ghrelin, and endocannabinoids.
Study: 10543929
Drug: Inogatran (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inogatran (low molecular mass direct thrombin inhibitor)
Study: 2201795
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (100 million units) recombinant alpha‐2b‐interferon